This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
In this issue we take a closer look at Cybin’s deuterated psilocybin analog (CYB003) Phase 2 interim results, sharing our thoughts from the company’s conference call. We cover topics such as participant drop-outs, blinding, and comparisons to other (psychedelic) drug candidates.
We also cover a number of developments in the UK, including a forthcoming report on barriers to research with controlled drugs (including psychedelics) that might offer concrete suggestions to the Government.
Elsewhere, we look at how a spat between Meta and its Oversight Board provides insight into how the future of ketamine-related adverts might pan out, how an effort to reschedule psilocybin in the U.S. has been given a lifeline, and two forthcoming studies of psychedelics in romantic relationships.
This issue’s contents:
Notes from the Conference Call: Cybin’s Deuterated Psilocybin Analog Results
Federal Appeals Court Throws Lifeline to Psilocybin Rescheduling Effort
UK Report on Barriers to Research with Controlled Drugs Expected to Publish Soon
Meta Ignores its Oversight Board’s Suggestions Regarding Ketamine Ads
‘Mushroom Pilot’ Case Sparks Soul-Searching
Leading UK Psychedelic Drug Policy Reform Group Rebrands, Founder Mired by Arrest
NIH to Establish and Fund a National Cannabis Research Centre
New NIDA Grant Opportunity for Psychedelics
Ethics Approval for Study of Psychedelics in Romantic Relationships
Other Headlines & Weekend Reads
To read this piece, head to our Join page to learn more, or sign in to your account.
